Article

Magnesium intake and risk of type 2 diabetes: Meta-analysis of prospective cohort studies

Department of Nutrition and Food Hygiene, Soochow University, Suzhou, China.
Diabetes care (Impact Factor: 8.57). 09/2011; 34(9):2116-22. DOI: 10.2337/dc11-0518
Source: PubMed

ABSTRACT Emerging epidemiological evidence suggests that higher magnesium intake may reduce diabetes incidence. We aimed to examine the association between magnesium intake and risk of type 2 diabetes by conducting a meta-analysis of prospective cohort studies.
We conducted a PubMed database search through January 2011 to identify prospective cohort studies of magnesium intake and risk of type 2 diabetes. Reference lists of retrieved articles were also reviewed. A random-effects model was used to compute the summary risk estimates.
Meta-analysis of 13 prospective cohort studies involving 536,318 participants and 24,516 cases detected a significant inverse association between magnesium intake and risk of type 2 diabetes (relative risk [RR] 0.78 [95% CI 0.73-0.84]). This association was not substantially modified by geographic region, follow-up length, sex, or family history of type 2 diabetes. A significant inverse association was observed in overweight (BMI ≥25 kg/m(2)) but not in normal-weight individuals (BMI <25 kg/m(2)), although test for interaction was not statistically significant (P(interaction) = 0.13). In the dose-response analysis, the summary RR of type 2 diabetes for every 100 mg/day increment in magnesium intake was 0.86 (95% CI 0.82-0.89). Sensitivity analyses restricted to studies with adjustment for cereal fiber intake yielded similar results. Little evidence of publication bias was observed.
This meta-analysis provides further evidence supporting that magnesium intake is significantly inversely associated with risk of type 2 diabetes in a dose-response manner.

0 Followers
 · 
150 Views
  • Source
    • "Mg 2C also takes part in cardiac excitability, and low levels of Mg 2C (hypomagnesemia) increase cardiac arrhythmias (Ganga et al., 2013; Vierling et al., 2013) and cardiovascular stroke (del Globbo et al., 2013; Joosten et al., 2013b; Qu et al., 2013), and low dietary intakes are associated with type 2 diabetes (Barbagallo and Dominguez, 2007; Kikuchi et al., 2012; Kirii et al., 2010; Lima et al., 2009; Munekage et al., 2012; Volpe, 2008); it is related as a cofactor in glucose transport through the cell as well as insulin secretion (Chaundry et al., 2010). This relationship between hypomagnesemia and the development of diabetes is even greater in insulin-resistant patients (Dong et al. 2011; Hata et al., 2013). In particular, a low level of Mg 2C is implicated in different pathological effects such as hypertension (Sontia and Touyz, 2007), has a pronounced effect in pregnancy3, and is associated with urinary excretion (Barbosa et al., 2005; Cunha et al., 2013; Joosten et al., 2013a; Kazemian et al., 201). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Magnesium is an essential mineral in human metabolism, and is the second most abundant intracellular cation and the fourth most abundant in the human body. Magnesium has a large variety of biological functions, including being a co-factor for over 300 enzymes, mainly involving phosphorylation of proteins and nucleic acids. Low levels of magnesium in the body can develop during different illness, such as diabetes (type 2), metabolic syndrome, cardiac arrhythmias and muscular constriction. The present review shows the advances in Analytical Chemistry based on sensor systems to quantify the concentration of magnesium in different biological samples, plasma, serum or urine, which are relevant to human health.
    Critical Reviews in Analytical Chemistry 01/2015; 45(1):32-40. DOI:10.1080/10408347.2013.867229 · 2.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study examined the association of dietary calcium intake with incident type 2 diabetes by a meta-analysis and explored the potential confounding by magnesium. Potential studies were identified by searching the PubMed database in September 2011. Prospective cohort studies that reported relative risks (RR) with 95% confidence intervals (CI) of type 2 diabetes for dietary calcium intake were selected. Results were combined using either a fixed- or random-effects model. Six prospective cohort studies comprising 264268 participants and 11225 reported cases were included. All combined random-effects meta-analysis yielded a significant pooled RR of 0.85 (95% CI 0.75-0.97). However, a sensitivity analysis limited to four studies with control for magnesium yielded an attenuated, nonsignificant pooled RR of 0.94 (95% CI 0.85-1.05). In conclusion, dietary calcium intake was not independently associated with risk of type 2 diabetes. The inverse association in prior observational studies may be partially confounded by magnesium intake.
    European journal of clinical nutrition 03/2012; 66(3):408-10. DOI:10.1038/ejcn.2012.5 · 2.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The magnesium content in food consumed in the Western world is steadily decreasing. Hypomagnesemia is associated with increased incidence of diabetes mellitus, metabolic syndrome, all-cause and coronary artery disease mortality. We investigated the impact of supplemental oral magnesium citrate versus magnesium oxide on intracellular magnesium levels ([Mg2+]i) and platelet function in healthy subjects with no apparent heart disease. In a randomized, prospective, double-blind, crossover study, 41 (20 women) healthy volunteers [mean age 53±8 (range 31-75) years] received either magnesium oxide monohydrate tablets (520 mg/day of elemental magnesium) or magnesium citrate tablets (295.8 mg/day of elemental magnesium) for one month (phase 1), followed by a four-week wash-out period, and then crossover treatment for one month (phase 2). [Mg2+]i was assessed from sublingual cells through x-ray dispersion (normal values 37.9±4.0 mEq/L), serum magnesium levels, platelet aggregation, and quality-of-life questionnaires were assessed before and after each phase. Oral magnesium oxide, rather than magnesium citrate, significantly increased [Mg2+]i (34.4±3 versus 36.3±2 mEq/L, p<0.001 and 34.7±2 versus 35.4±2 mEq/L, p=0.097; respectively), reduced total cholesterol (201±37 versus 186±27 mg/dL, p=0.016 and 187±28 versus 187±25 mg/dL, p=0.978; respectively) and low-density lipoprotein (LDL) cholesterol (128±22 versus 120±25 mg/dL, p=0.042 and 120±23 versus 121±22 mg/dL, p=0.622; respectively). Noteworthy is that both treatments significantly reduced epinephrine-induced platelet aggregation (78.9±16% versus 71.7±23%, p=0.013 and 81.3±15% versus 73.3±23%, p=0.036; respectively). Thus, oral magnesium oxide treatment significantly improved [Mg2+]i, total and LDL cholesterol compared with magnesium citrate, while both treatments similarly inhibited platelet aggregation in healthy subjects with no apparent heart disease.
    Magnesium research: official organ of the International Society for the Development of Research on Magnesium 03/2012; 25(1):28-39. DOI:10.1684/mrh.2012.0305 · 1.56 Impact Factor
Show more